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chronic obstructive pulmonary disease (COPD). We recently demonstrated involvement of the inﬂammatory
classical NF-κB pathway in inﬂammation-induced impairments in muscle OXPHEN. The exact underlying
mechanisms however are unclear. Interestingly, IκB kinase α (IKK-α: a key kinase in the alternative
NF-κB pathway)was recently identiﬁed as a novel positive regulator of skeletalmuscleOXPHEN.Wehypothesised
that inﬂammation-induced classical NF-κB activation contributes to loss of muscle OXPHEN in COPD by reducing
IKK-α expression. Methods: Classical NF-κB signalling was activated (molecularly or by tumour necrosis factor
α: TNF-α) in culturedmyotubes and the impact onmuscle OXPHEN and IKK-α levels was investigated. Moreover,
the alternative NF-κB pathway was modulated to investigate the impact on muscle OXPHEN in absence or
presence of an inﬂammatory stimulus. As a proof of concept, quadriceps muscle biopsies of COPD patients and
healthy controls were analysed for expression levels of IKK-α, OXPHEN markers and TNF-α. Results: IKK-α
knock-down in cultured myotubes decreased expression of OXPHEN markers and key OXPHEN regulators.
Moreover, classical NF-κB activation (both by TNF-α and IKK-β over-expression) reduced IKK-α levels and
IKK-α over-expression prevented TNF-α-induced impairments in muscle OXPHEN. Importantly, muscle IKK-α
protein abundance and OXPHEN was reduced in COPD patients compared to controls, which was more
pronounced in patients with increased muscle TNF-α mRNA levels. Conclusion: Classical NF-κB activation
impairs skeletal muscle OXPHEN by reducing IKK-α expression. TNF-α-induced reductions in muscle IKK-α
may accelerate muscle OXPHEN deterioration in COPD.
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Loss of quadriceps muscle oxidative phenotype (OXPHEN) is a
well-recognised feature of chronic obstructive pulmonary disease
(COPD) and signiﬁcantly impairs muscle endurance, exercise ca-
pacity and quality of life in patients [1,2]. Moreover, loss of muscle
OXPHEN has been postulated as a driver of muscle wasting and
cardiovascular/metabolic risk in COPD, both of which contribute
signiﬁcantly to morbidity and mortality of the disease [3,4]. Impor-
tantly, the muscle phenotype is not uniform [5] so understanding
aetiological drivers of key subsets is necessary for therapeutic
advances.
Collectively, loss of muscle OXPHEN in COPD includes a ﬁbre-type
shift from type I (slow, oxidative) to type II (fast, glycolytic) ﬁbres,
decreased muscle mitochondrial content and reduced activity levels
of metabolic enzymes involved in substrate oxidation pathways
[6–8]. Moreover, decreased expression levels of constituents of the
PGC-1/PPAR signalling pathway, a key pathway regulating cellular
OXPHEN, have been shown in the musculature of COPD patients
[9,10].
The exact triggers and molecular mechanisms leading to loss
of muscle OXPHEN in COPD remain obscure. However, chronic
(systemic) inﬂammation, frequently associated with COPD [11],
has been implicated in muscle OXPHEN deterioration observed in
COPD [3]. Indeed, we previously showed that expression levels of key
OXPHEN constituents were reduced in quadriceps muscle of COPD
patients with elevated levels of the pro-inﬂammatory cytokine tumour
necrosis factor α (TNF-α) in muscle compared to healthy controls and
compared to patients with normal muscle TNF-α levels. Stimulation of
cultured myotubes with TNF-α subsequently revealed that this cyto-
kinedirectly impairsmuscle OXPHEN and reduces Pgc-1/Ppar signalling
[12]. Furthermore, we recently showed that inﬂammation-induced loss
of muscle OXPHEN requires activation of the classical NF-κB pathway
[13], a key inﬂammatory signalling pathway which is of particular
importance as increased classical NF-κB activation has been demon-
strated in skeletal muscle of patients with severe COPD [14,15].
Under normal physiological conditions, the classical NF-κB sub-unit
Rela/P65 is maintained primarily in the cytoplasm bound to an IκB
repressor molecule. Active classical NF-κB signalling is triggered
when inﬂammatory stimuli, such as TNF-α initiate the rapid phos-
phorylation and degradation of IκBα through Ikk-β kinase activity.
This liberates Rela to move into the nucleus and initiate transcription
of NF-κB target genes [16].
The down-stream effector and the mechanisms of classical NF-κB
activation-mediated impairment of skeletal muscle OXPHEN are un-
known. Interestingly, Bakkar et al. recently identiﬁed IκB kinase α
(Ikk-α), a key kinase in the alternative NF-κB pathway, as a novel posi-
tive regulator of skeletal muscle OXPHEN. These authors showed that
Ikk-α improves muscle OXPHEN through direct transcriptional control
of Pgc-1-mediated signalling [17]. It however remains to be determined
whether or not the role of the alternative NF-κB pathway in the regula-
tion of muscle OXPHEN is compromised by (inﬂammation-induced)
classical NF-κB activation and whether or not impairments in the alter-
native NF-κB pathway contribute to loss of muscle OXPHEN observed
in COPD.
Therefore, in the current translational study, we hypothesised
that (inﬂammation-induced) classical NF-κB activation impairs
skeletal muscle OXPHEN by reducing Ikk-α expression and that
loss of muscle OXPHEN in COPD is associated with decreased levels
of muscle IKK-α protein and an increased muscle inﬂammatory
status. We therefore investigated whether classical NF-κB activa-
tion by TNF-α or Ikk-β over-expression impedes on Ikk-α-mediated
regulation of muscle OXPHEN in cultured myotubes and explored
muscle OXPHEN as well as IKK-α and TNF-α levels in quadriceps
muscle biopsies from a large group of COPD patients and healthy
controls.2. Materials and methods
2.1. Cell culture
The murine C2C12 skeletal muscle cell line was obtained from the
American Type Culture Collection (ATCC CRL1772; Manassas, VA,
USA). The stable C2C12 NF-κB transcriptional activity reporter cell line
was constructed as described previously [18] and C2C12-IκBα-SR cells
(displaying blocked classical NF-κB signalling) were kindly provided
by Dr. Guttridge (Ohio State University, OH, USA). The stable Ppar re-
porter cell line was constructed and cultured as described previously
[12]. C2C12 myoblasts were cultured and differentiated into mature
multi-nucleated myotubes as described previously [18]. Myotubes
were differentiated for 5 days after which hormonal (TNF-α) or molec-
ular interventions (Ad-Gfp, Ad-Ikk-β, Ad-Ikk-α or SiRNA)were initiated
for the indicated time. Additional detail regarding culture conditions is
provided in the online data supplement.2.2. Transfections and plasmids
For the assessment of NF-κB transcriptional activity or Ppar tran-
scriptional activity, C2C12 cells were stably transfected with a 6κB-TK
luciferase plasmid (NF-κB reporter) or a HCBP (Human CPT-I B promot-
er) reporter plasmid (Ppar reporter) as previously described [12,18].
Details regarding transfection procedures and reporter assays are pro-
vided in the online data supplement.2.3. Western blot & quantitative Pcr (Q-Pcr)
Details regarding preparation of whole-cell lysates and western
blotting procedures as well as information regarding RNA isolation,
cDNA synthesis and Q-PCR can be found in the online data supplement.2.4. Enzyme activity assay
Activity of β-hydroxyacyl-CoA dehydrogenase (Had) (EC 1.1.1.35)
was measured as described previously [19]. Enzyme activity levels
were measured at 37○C and at PH 7.3 and were corrected for total
protein content which was determined using a detergent compatible
protein determination assay (Bio-Rad Hercules, CA, USA).2.5. ATP assay
Details about the ATP assay are provided in the online data
supplement.2.6. Subjects
For the human study, we analysed remaining quadriceps muscle bi-
opsies of clinically stable COPD patients and healthy controls obtained
from 2 cohorts previously published as an ENIGMA study [12] and a
study within the framework of the Dutch Top Institute Pharma (TIP)
[20]. Written consent was obtained from all subjects and the study
was approved by the ethical review boards of the different European
centres. These studies have been carried out in accordancewith the dec-
laration of Helsinki. Data within each cohort (lung function and muscle
gene expression) were expressed as a percentage of their respective
control group (to reduce the risk for any potential selection bias) and
data from these 2 cohorts were pooled. Additional details regarding
inclusion and exclusion criteria, collection and processing of muscle
biopsies andmethodology for assessment of lung function are provided
in the online data supplement.
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Data was analysed according to the guidelines of Altman et al.
using SPSS (SPSS Inc., Chicago, IL, USA) [21]. Unpaired, independent
student t-tests (corrected for unequal variances if appropriate) or
one-way ANOVA analyses with an LSD post hoc correction were used
when appropriate. Linear regression was applied to correct for any
inter-cohort differences in the human muscle biopsy analyses. The
Pearson correlation test was used to explore relevant correlations.
Where appropriate data was transformed as log (x) to correct for non-
linearity. In addition, if natural zero values were observed and log
transformation was appropriate data was transformed as log (x + 1).
Data are represented as the mean ± SD or mean ± SEM as indicated.
A p-value of less than 0.05 was considered to be signiﬁcant.
3. Results
3.1. Loss of Ikk-α expression disturbs skeletal muscle oxidative phenotype
To conﬁrm and extend the dependency of muscle cell OXPHEN on
Ikk-α, Ikk-α was silenced in cultured myotubes. SiRNA molecules
targeting Ikk-α effectively reduced both Ikk-αmRNA and protein levels
by approximately 70% (Fig. S1A–C). Ikk-α knock-down subsequently
resulted in reduced protein and mRNA levels of sub-units of mitochon-
drial oxidative phosphorylation (Oxphos) complexes, reduced activity
of Had (β-hydroxyacyl-CoA dehydrogenase: the rate-limiting enzyme
in fatty acid β-oxidation) and a decreased intra-cellular ATP content
(Fig. 1A–F). Furthermore, knock-down of IKK-α resulted in signiﬁcantly
decreased protein levels of type I, slow myosin heavy chain (Myhc)
while type II, Myhc fast protein levels remained unaffected. Protein
levels of the fast isoforms of myosin light chain (Mlc) 3 and Mlc 1
tended to increase upon Ikk-α knock-down (Fig. 1G, H). In addition,
mRNA levels of the slow Myhc I and Myhc IIa isoforms decreased
while mRNA levels of the fast isoform Myhc IIb increased in response
to Ikk-α knock-down (Fig. 1I–K). Myhc IIx mRNA levels were largely
unaltered (data not shown). Ikk-α knock-down reduced Pgc-1α as
well as Pgc-1β mRNA transcript levels and decreased Ppar transcrip-
tional activity (Fig. 1L, M). mRNA expression levels of Ppar-δ, Tfam,
Nrf-1 and Nrf-2α were unaltered in response to loss of Ikk-α protein.
Collectively, this data shows that loss of Ikk-α protein reduces muscle
OXPHEN and impedes on the molecular regulation of muscle OXPHEN
by interfering with the Pgc-1/Ppar signalling pathway.
3.2. Classical NF-κB Decreases Muscle Ikk-α Expression
We previously convincingly demonstrated that TNF-α impairs mus-
cle OXPHEN [12]. In addition, as indicated in Fig. S2, TNF-α stimulation
of C2C12myotubes thatwere differentiated for 5 days potently reduced
mRNA expression levels of markers and regulators of muscle OXPHEN
in absence of a change in mitochondrial DNA (mtDNA) content
(Fig. S2A–E). In light of the data presented in Fig. 1, we next investigated
Ikk-α protein levels in cultured myotubes in response to TNF-α stimu-
lation. As depicted in Fig. 2A, Ikk-α protein content was signiﬁcantly re-
duced in wild-type C2C12myotubes chronically stimulatedwith TNF-α
(Fig. 2A). To verify whether this represented a speciﬁc effect on Ikk-α,
Ikk-β protein content was determined after TNF-α exposure and
found not to be signiﬁcantly altered (Fig. S3A). We previously demon-
strated that TNF-α-induced deterioration of muscle OXPHEN depends
on activation of the inﬂammatory signalling pathway classical NF-κB
[13]. In the present study, increased expression of a known target
gene of the classical NF-κB pathway (intra-cellular adhesion molecule
1: Icam-1) and potent nuclear translocation of themain transcriptionally
active sub-unit: Rela (Fig. S4A–B) reﬂected classical NF-κB activation fol-
lowing TNF-α stimulation of cultured myotubes. To investigate whether
intact classical NF-κB signalling is required for TNF-α-induced loss of
muscle Ikk-α expression, we blocked the classical NF-κB pathway bytransient or stable transfection of a non-degradable form of the repres-
sor of classical NF-κB signalling IκBα (IκBα-SR). Effectiveness of stable
NF-κB blockade in C2C12myotubes is shown in Fig S4 A-D. Interesting-
ly, C2C12myotubeswith blocked classical NF-κB signallingwere refrac-
tory to TNF-α-induced reductions in Ikk-α protein (Fig. 2B). Also,
although TNF-α reduced Ikk-α mRNA levels in wild-type C2C12
myotubes, myotubes from the IκBα-SR C2C12 cell line were refractory
to TNF-α-induced reductions in Ikk-α mRNA levels (Fig. 2C). In addi-
tion, TNF-α reduced Ikk-α promoter activity in wild-type C2C12 cells
but not in IκBα-SR C2C12 cells (Fig. 2D). In coherence, TNF-α-induced
reductions in Ikk-α promoter activity were abrogated in C2C12 cells
transiently expressing a non-degradable IκBα construct (Fig. 2E).
To investigate whether activation of classical NF-κB signalling, in
absence of inﬂammatory cytokines, is sufﬁcient to reduce Ikk-α
expression, classical NF-κB signalling was activated by adenoviral
(Ad) delivery of Ikk-β, a key kinase in the classical NF-κB pathway. As
illustrated in Fig. 3, Ad-Ikk-βdelivery to C2C12myotubes resulted in po-
tent Ikk-β over-expression (Fig. 3A) and activation of NF-κB transcrip-
tional activity (Fig. 3B). Ikk-β over-expression subsequently decreased
both Ikk-α protein and mRNA levels in C2C12 myotubes (Fig. 3C, D).
In line with protein and mRNA data, over-expression of a constitutive
active form of Ikk-β diminished Ikk-α promoter activation (Fig. 3E).
Collectively this data shows that activation of classical NF-κB signal-
ling is required and sufﬁcient for (TNF-α-induced) loss of muscle Ikk-α
expression.
3.3. Ikk-α Over-Expression Prevents TNF-α-Induced Impairments in Muscle
OXPHEN
We next investigated whether over-expression of Ikk-α protein
could prevent TNF-α-induced impairments in muscle OXPHEN (as we
have previously reported [12,13]). As depicted in Fig. 4, Ikk-α was po-
tently over-expressed and TNF-α-induced decreases in Ikk-α protein
levels were restored by adenoviral over-expression of Ikk-α (Fig. 4A,
B). Ikk-α over-expression increased Myhc slow protein content and
TNF-α-induced reductions in Myhc slow protein content were attenuat-
ed by Ikk-α over-expression (Fig 4A, C). Similarly, Ikk-α over-expression
increased Myhc I mRNA levels and TNF-α-induced reductions in Myhc I
mRNA transcript abundance were abrogated when Ikk-α was over-
expressed (Fig 4D). Cyc1 and Sdhb mRNA levels, as representative
OXPHOS markers, were increased upon Ikk-α over-expression. In addi-
tion, both Cyc1 and Sdhb mRNA levels decreased upon TNF-α exposure
whereas this reduction was not observed when exogenous Ikk-α was
expressed (Fig 4E, F). Furthermore, Ikk-α over-expression increased
Pgc-1α, not Pgc-1β, mRNA levels and prevented TNF-α-induced reduc-
tions in Pgc-1α and Pgc-1βmRNA levels (Fig 4G, H).
3.4. Skeletal muscle IKK-α protein abundance is reduced in COPD
As expected, COPD patients had an impaired muscle oxidative phe-
notype evidenced by reduced muscle gene expression levels of HAD,
Citrate synthase (CS), Cytochrome c oxidase sub-unit IV (COX IV),
PPAR-α and PGC-1α (keymarkers/regulators of muscle OXPHEN) com-
pared to controls (Table 1). Furthermore, IKK-α protein levels were sig-
niﬁcantly lower in quadriceps muscle biopsies from COPD patients
compared to healthy controls (Fig. 5A). Muscle TNF-α mRNA levels
were signiﬁcantly higher in patients compared to healthy subjects
(Table 1). Regression analysis revealed that differences in levels of
TNF-α, IKK-α, HAD, COX IV, PGC-1α and PPAR-α observed between
COPD patients and controlswere independent ofwhich of the two stud-
ies the biopsies came from.
The subset of patientswith high levels of TNF-αmRNA inmuscle not
only displayed lower levels of CS, HAD, COX IV and PPAR-α but also sig-
niﬁcantly lower levels of muscle IKK-α protein compared to patients
with normal muscle TNF-α levels (Table 1) (Fig. 5B). Additionally, in
the whole study population (n = 81) muscle TNF-α levels correlated
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and when COPD patients only (n = 59) were considered in isolation
(r = −0.279, p = 0.032). Also, in both the whole study population
and also in COPD patients considered alone, IKK-α protein levels corre-
lated positively with HAD (r = 0.440 and r = 428 respectively;
p ≤ 0.001) and with parameters of lung function as FEV1 (r = 0.473
and r = 0.427, p ≤ 0.001). Hence, muscle TNF-α levels correlated in-
versely with FEV1 (r = −0.417 and r = −0.369, p ≤ 0.01) and in-
versely with HAD (r = −0.484 and r = −0.485; p ≤ 0.001) (Fig. 6).
Differences in OXPHEN markers between COPD patients with high
muscle TNF-α levels and normal TNF-α levels remained statistically
signiﬁcant after inclusion of study group as an independent variable.
However, although IKK-α protein levels were signiﬁcantly lower in
patients with high muscle TNF-α levels compared to patients with
normal TNF-α levels and healthy controls in an ANOVA test, this statis-
tically signiﬁcant difference was dissipated when the study source was
included as an independent variable in our regression model.4. Discussion
The present study is the ﬁrst to reveal that TNF-α-induced classical
NF-κB activation reduces Ikk-α expression levels in skeletal muscle.
Loss of Ikk-α protein subsequently resulted in an impaired muscle
OXPHEN as restoring Ikk-α levels proved to be sufﬁcient to prevent
TNF-α-induced impairments in muscle OXPHEN. Moreover, analysis of
human skeletal muscle biopsies revealed that muscle IKK-α protein
content was signiﬁcantly lower in COPD patients compared to healthy
controls, which was accompanied by an impaired muscle OXPHEN
and, interestingly, was more pronounced in patients with high muscle
TNF-α levels. Collectively, these data suggest a role for loss of IKK-α
expression in inﬂammation-induced impairment of muscle OXPHEN
with relevance for a signiﬁcant subset of patients with COPD.
We previously demonstrated that inﬂammatory cytokines as TNF-α
potently reducemuscle OXPHEN [12]. As it is known that inﬂammatory
cytokines can inhibit myogenic differentiation [18] and we previously
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Fig. 3. Classical NF-κB activation decreasesmuscle Ikk-α expression. a) C2C12myotubes (differentiated for 5 days)were infectedwith an adenoviral (Ad) construct expressing Ikk-β or an
Ad-Gfp construct (control) for 120 h (2 × 107 PFU/ml). Ikk-β over-expression was veriﬁed bywestern blot analysis. Western blot data was corrected for total protein content and Gapdh
was used as a loading control. b) C2C12myoblasts stably expressing a NF-κB responsive luciferase construct (6-κB TK luciferase) were differentiated for 5 days in differentiationmedium
into fullymaturemyotubes.Myotubeswere stimulatedwith Ad-Ikk-β orAd-Gfp for the indicated time. Luciferase activitywas determined and normalised for total protein. c, d)Wild-type
(WT) C2C12myotubeswere infectedwith an adenoviral construct expressing Ikk-β or an Ad-Gfp construct as control for 120 h (c) or 72 h (d). Cells were harvested at the indicated time-
points and Ikk-α protein andmRNAwere determined bywestern blotting andQ-PCR respectively.Western blots were corrected for total protein andGapdhwas used as a loading control.
e) WT C2C12 myoblasts were transfected with an Ikk-α promoter reporter construct and an empty vector as a control or a constitutive active (c.a.) Ikk-β expression construct. 24 h
after transfection, cells were harvested, luciferase activity was determined and normalised for β-galactosidase activity. Values are expressed as mean ± SD from triplicate samples
(experiments n = 3). Signiﬁcance compared to control: * p ≤ 0.05.
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shift towards a more oxidative metabolic proﬁle [22], we veriﬁed that
TNF-α-induced decreases in expression levels ofmarkers and regulators
of muscle OXPHEN represented a true decline in cellular OXPHEN
and not a delayed development of muscle OXPHEN due to impaired
myogenesis. This is in line with our previous ﬁndings which demon-
strated that TNF-α stimulation of myotubes that have undergone the
myogenic differentiation programme for several days potently de-
creased cellular OXPHEN but failed to affect myogenic index and crea-
tine kinase activity (as markers for myogenic differentiation) [23]. In
addition, we further characterised the impact of TNF-α on cultured
myotube OXPHEN by assessing TNF-α-induced alterations in mtDNA
content. Although TNF-α clearly impaired myotube OXPHEN, no signif-
icant changes were observed in mtDNA content upon chronic TNF-α
stimulation. This is in line with a recent report from Rowe et al. which
demonstrated that muscle OXPHEN was heavily impaired in absence
of alterations in mitochondrial content in mice lacking both Pgc-1α
and Pgc-1β in muscle [24]. By applying electron microscopy, these au-
thors uncovered that muscle mitochondria of mice lacking both Pgc-1
moleculeswere less densely packedwith components of the respiratoryFig. 4. Ikk-α over-expression prevents TNF-α-induced impairments inmuscle OXPHEN. a-c)Wi
(Ad) construct expressing Ikk-α or anAd-Gfp construct as control for 48 h (2 × 107 PFU/ml). Af
(10 ng/ml) for an additional 72 h. Cells were harvested and Myhc slow, Myhc fast and Ikk-α pr
protein and Gapdhwas used as a loading control. d–h)Wild-type (WT) C2C12myotubeswere i
ulatedwith vehicle (bovine serum albumin; Control) or TNF-α (10 ng/ml) for an additional 48 h
Pgc-1βwere determined by Q-PCR. Values are expressed as mean ± SD from triplicate sampleelectron transport chain which explains the loss of oxidative capacity
without an apparent decrease in mitochondrial DNA content.
Inﬂammatory cytokines as TNF-α are potent activators of the classi-
cal NF-κB pathway [16]. In the present study, similar to TNF-α-induced
classical NF-κB activation, activation of classical NF-κB signalling by Ikk-
β over-expression (in absence of inﬂammatory cytokines) decreased
Ikk-α protein and mRNA expression and Ikk-α promoter activation
showing that activation of classical NF-κB per se is sufﬁcient to reduce
muscle Ikk-α expression. Given the novel role of Ikk-α in the regulation
of skeletal muscle OXPHEN [17], whichwe have conﬁrmed and extend-
ed in this study, this observation is coherent with our previous ﬁndings.
Indeed, we recently demonstrated that activation of classical NF-κB
signalling by TNF-α, but also by interleukin 1β (Il-1β) or by over-
expression of Ikk-β, is sufﬁcient to impair muscle OXPHEN evidenced
by reduced expression levels of mitochondrial proteins, altered mito-
chondrial morphology and by decreases in expression levels of genes
involved in mitochondrial biogenesis and mitochondrial fusion and ﬁs-
sion [13]. In light of these observations, inﬂammatory cytokines other
than TNF-α known to induce activation of classical NF-κB signalling
(as e.g. IL-1β) may well impair muscle OXPHEN in an Ikk-α-mediatedld-type (WT) C2C12myotubes (differentiated for 5 days) were infectedwith an adenoviral
ter 48 hmyotubeswere stimulatedwith vehicle (bovine serumalbumin; Control) or TNF-α
otein content was determined by western blotting. Western blots were corrected for total
nfected with an Ad-Ikk-α or an Ad-Gfp construct for 48 h. After 48 hmyotubeswere stim-
.mRNA expression levels ofMyhc I andOXPHOS complexes II and III aswell as Pgc-1α and
s (experiments n = 3). Signiﬁcance compared to control: * p ≤ 0.05.
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Table 1
Subject characteristics. All markers of muscle oxidative phenotype as well as TNF-α levels are expressed as gene expression data. FEV1: Forced expiratory volume in 1s. FVC: Forced vital
capacity. BMI: Bodymass index. CS: Citrate synthase. HAD: β-hydroxyacyl-CoA dehydrogenase. COX IV: Cytochrome c oxidase sub-unit IV. PPAR-α: Peroxisome proliferator-activated re-
ceptor α. PGC-1α: PPAR-γ co-activator 1α. TNF-α: Tumour necrosis factor α. Values are expressed as mean ± SD except for gene expression data which is presented as mean ± SEM.
Signiﬁcance compared to healthy controls: * p ≤ 0.05; Signiﬁcance compared to the “normal TNF-α” COPD subgroup: # p ≤ 0.05.
Controls (n = 22) COPD (n = 59) COPD Normal TNF-α (n = 36) COPD High TNF-α (n = 23)
Age (years) 61.5 ± 9.1 64.1 ± 7.5 64.4 ± 7.9 63.7 ± 6.9
Sex (M/F) 13/9 42/17 22/14 20/3
Lung function
FEV1 (% predicted) 102.7 ± 20.4 46.9 ± 18.4⁎ 51.4 ± 18.6⁎ 39.8 ± 16.0⁎ #
FVC (% predicted) 110.1 ± 21.3 90.0 ± 26.0⁎ 94.9 ± 22.6 82.3 ± 6.2⁎ #
Body composition
Weight (kg) 73.1 ± 16.0 70.6 ± 12.4 70.1 ± 11.0 71.3 ± 14.6
BMI 25.5 ± 4.2 24.8 ± 4.0 25.1 ± 4.1 24.3 ± 4.0
Muscle oxidative phenotype
CS (% of control) 100.0 ± 5.0 84.5 ± 4.2⁎ 93.9± 4.7 69.8 ± 6.9⁎ #
HAD (% of control) 100.0 ± 4.0 76.9 ± 3.6⁎ 85.1 ± 3.9⁎ 64.2 ± 6.1⁎ #
COX IV (% of control) 100.0 ± 5.2 88.1 ± 3.1⁎ 92.8 ± 4.0 80.7 ± 4.4⁎ #
PGC-1α (% of control) 100.0 ± 8.6 76.1 ± 5.2⁎ 77.1 ± 6.1⁎ 74.6 ± 9.4⁎
PPAR-α (% of control) 100.0 ± 5.5 84.9 ± 3.5⁎ 92.8 ± 4.8 72.6 ± 3.9⁎ #
Muscle inﬂammation
TNF-α (% of control) 100.0 ± 15.7 202.6 ± 24.4 ⁎ 83.8 ± 9.0 388.7 ± 35.3⁎ #
182 A.H.V. Remels et al. / Biochimica et Biophysica Acta 1842 (2014) 175–185mechanism similar to TNF-α. Also, in the present study we show that
TNF-α-induced reductions in Ikk-α expressionwere convincingly dissi-
pated upon abrogation of classical NF-κB signalling, indicating that acti-
vation of classical NF-κB activation is a prerequisite for inﬂammatory
mediator-induced loss of Ikk-α expression. Again, this is in line with
previous ﬁndings from our group showing that TNF-α-induced impair-
ments in muscle OXPHEN were abrogated in myotubes with defective
classical NF-κB signalling [12,13]. Moreover, over-expression of Ikk-α
protein prevented TNF-α-induced reductions in the expression of
slow Myhc and OXPHOS complexes, demonstrating that loss of Ikk-α
expression is causally related to TNF-α-induced impairments in skeletal
muscle OXPHEN.
The molecular mechanism by which classical NF-κB activation
reduces Ikk-α expression levels remains to be established. Our data
shows that activation of classical NF-κB signalling decreases Ikk-α120
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Fig. 5. Skeletal muscle IKK-α protein content is reduced in COPD. Skeletal muscle biopsies
were obtained from a group of COPD patients (n = 59) and a group of healthy controls
(n = 22). a, b) IKK-α protein was determined by western blotting. Western blots were
corrected for total protein and GAPDH was used as a loading control. A representative
Western blot is shown. Values are expressed as mean ± SEM. Signiﬁcance: * p ≤ 0.05;
# p ≤ 0.1.promoter activation. The classical NF-κB transcriptionally active sub-
unit Rela has been described to be able to mediate promoter repression
upon binding to a target sequence [25]. However, no NF-κB responsive
elements have been described in the Ikk-α promoter arguing against di-
rect binding of NF-κB sub-units to the Ikk-α promoter regionmediating
inhibition [26]. In addition, transcription of the Ikk-α promoter is nega-
tively regulated by P53 [27] and multiple P53 responsive elements are
present in the Ikk-α promoter reporter constructwe used [28]. Interest-
ingly, P53 was recently shown to positively affect muscle OXPHEN [29].
Whether or not P53 is involved in classical NF-κB-induced inhibition of
Ikk-α promoter activity remains to be determined. Additionally, recent-
ly, miR-223, miR-15a and miR-16 were identiﬁed as potent negative
regulators of Ikk-α protein abundance in macrophages [30]. miR-223,
miR-15a and miR-16 are expressed in skeletal muscle [31–33] and
miR-223 andmiR-16 have been shown to be up-regulated in conditions
in which TNF-α levels are elevated [34,35]. Moreover, miR-16 is under
direct transcriptional control of the classical NF-κB pathway [36]. There-
fore, increased levels of these miRNAmolecules might well be involved
in post-transcriptional regulation of Ikk-α protein content in skeletal
muscle under chronic inﬂammatory conditions.
Although the exact molecular mechanism remains to be elucidated,
our data clearly shows that (TNF-α-induced) classical NF-κB activation
reduces Ikk-α protein with a subsequent detrimental impact onmuscle
OXPHEN. Intriguingly, the alternative NF-κB pathway (of which Ikk-α is
an essential constituent) and the classical NF-κB pathway appear to play
opposing roles during the regulation of myogenic differentiation in
which development of cellular OXPHEN is crucial to meet themetabolic
demands of newly formed muscle ﬁbres. More speciﬁcally, activity of
the classical NF-κB pathwaywas shown to diminish duringmyogenesis
while activity of the alternative pathway was potently induced [37,38].
This is suggestive of an antagonistic relationship between classical and
alternative NF-κB signalling in the regulation of muscle OXPHEN,
which is in line with our data. Conversely, Ikk-α also is a known nega-
tive regulator of the classical NF-κB pathway. A recent study reported
that Ikk-α inhibits classical NF-κB signalling by phosphorylating multi-
ple substrates that together coordinate repression of classical NF-κB sig-
nalling [39]. In this context, it can be speculated that loss of Ikk-α
protein relieves negative feed-back on the classical NF-κB pathway
thereby potentiating detrimental effects of activation of this pathway
on skeletal muscle OXPHEN as we previously reported [12,13].
Bakkar et al. recently showed that muscle-speciﬁc knock-out of Ikk-
α in vivo impaired muscle OXPHEN and decreased levels of Pgc-1β, not
Pgc-1α, whichwas in linewith their ﬁndings that identiﬁed Pgc-1β as a
HAD mRNA
Control
COPD
HAD mRNA
Lo
g 
IK
K-
αα
 
pr
ot
ei
n 
Log FEV1
Control
COPD
Control
COPD
Control
COPD
Lo
g 
TN
F-
α
 
m
R
N
A
 
Log FEV1
,50
,40
,30
,20
,10
,00
,00 ,25 ,50 ,75 1,00 1,25
,00 ,25 ,50 ,75 1,00 1,25
,50
,40
,30
,20
,10
,00
1,00 1,20 1,40 1,60 1,80 2,00 2,20
1,00 1,20 1,40 1,60 1,80 2,00 2,20
1,20
1,00
,80
,60
,40
,20
,00
1,20
1,00
,80
,60
,40
,20
,00
Lo
g 
TN
F-
α
 
m
R
N
A
 
Lo
g 
IK
K-
α
 
pr
ot
ei
n 
Fig. 6. Correlations between muscle IKK-α, TNF-α, HAD and FEV1. Correlations between muscle IKK-α, muscle TNF-α and muscle HADmRNA expression as well as FEV1 were explored
with a Pearson correlation test.
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trast with ﬁndings from Bakkar et al. loss of Ikk-α protein in our study
was associated with decreased mRNA transcript levels of both Pgc-1α
and Pgc-1β. Moreover, Ikk-α over-expression potently increased Pgc-
1α, not Pgc-1β, mRNA levels and TNF-α-induced reductions in Pgc-1α
and Pgc-1β mRNA levels were both prevented by over-expression of
Ikk-α. Collectively, this suggests that Ikk-α is involved in the regulation
of muscle OXPHEN through control over both Pgc-1α and Pgc-1β. The
reason for the apparent contradiction with results from Bakkar et al.
may be explained by differences in the applied methodology. In the
present study, we modulated Ikk-α C2C12 myotubes that were differ-
entiated for 5 days which, as our data shows, display a near fully devel-
oped OXPHEN. In contrast, Bakkar et al. modulated Ikk-α protein
content in C2C12myoblasts after which themyogenic programwas ini-
tiated. As the expression of both Pgc-1α and Pgc-1β are induced during
myogenic differentiation [17,22], the observed effects of Ikk-αmodula-
tion on expression of the Pgc-1 molecules in the latter approach might
reﬂect differential regulation of Pgc-1α and Pgc-1β by Ikk-α modula-
tion during myogenesis rather than regulation of the Pgc-1 molecules
by Ikk-α inmyotubeswith a ﬁxed, fully developedOXPHEN. In addition,
Bakkar et al. applied adeno-associated viral (AAV) Ikk-α expression
constructs to over-express Ikk-α in vivo and subsequently investigate
effects on the regulation of muscle OXPHEN by Pgc-1molecules, where-
as we applied adenoviral expression (Ad) constructs which may yield
higher levels of over-expression as compared to AAV constructs.
Both muscle OXPHEN as well as PGC-1/PPAR signalling are compro-
mised in skeletal muscle of COPD patients [9,40,41]. Interestingly, our
own work and that of Bakkar et al. shows that loss of muscle Ikk-α
expression in vitro and in vivo, recapitulates many of the alterationsobserved in COPD-associated loss of muscle OXPHEN. Indeed, loss of
muscle Ikk-α protein content resulted in decreased expression levels
of mitochondrial proteins and impairments in the Pgc-1/Ppar pathway,
similar as to what is observed in COPD [9]. In fact, in the present manu-
script we show, for the ﬁrst time, that an impaired muscle OXPHEN and
decreasedmuscle PGC-1/PPAR signalling in COPD are indeed associated
with a reduced muscle IKK-α protein content. In addition, knock-down
of Ikk-α in cultured myotubes in our hands resulted in signiﬁcantly de-
creased levels of Myhc I and IIA (slow) isoforms while expression the
Myhc IIb (fast) isoform was signiﬁcantly induced. Although in humans
MYHC IIb is only expressed at very low levels inmuscle, human skeletal
muscle does express high levels of MYHC I and MYHC IIa. As muscle of
COPD patients is often characterised by a reduction in the proportion
of type I (slow, oxidative) ﬁbres, loss of IKK-α, may well contribute to
the ﬁbre-type shift towards a more glycolytic distribution that is often
observed in this disease [7].
In addition to an impaired muscle OXPHEN [7,42,43] and disturbed
PGC-1 signalling [9,12], increased activation of inﬂammatory signalling
(classical NF-κB) has been described in the musculature of severe COPD
patients [44]. In our study, reductions in IKK-α protein as well as im-
pairments in muscle OXPHEN appeared more pronounced in COPD
patients with high levels of muscle TNF-α expression. Moreover, IKK-
α levels in muscle correlated inversely with muscle TNF-α in the total
group of investigated subjects as well as in the COPD patient group
only. In concert with our in vitro data, this strongly suggests that
TNF-α-induced reductions in muscle IKK-α may accelerate muscle
OXPHEN deterioration in COPD. Although we observed that loss of
Ikk-α in vitro resulted in decreased expression levels of both Pgc-1β
and Pgc-1α and that COPD patients with high levels of muscle TNF-α
184 A.H.V. Remels et al. / Biochimica et Biophysica Acta 1842 (2014) 175–185displayed lower levels of IKK-α, PGC-1α expressionwas not signiﬁcant-
ly different in this sub-set of patients compared to patients with normal
TNF-α levels despite a signiﬁcantly more impaired muscle OXPHEN.
The reason for this is unclear but may be related to the multi-factorial
nature of the disease or to inherent differences between cell culture
models and intact human muscle in vivo. As we show that TNF-α-
induced decreases in Ikk-α protein levels in mature myotubes repre-
sent a true decline in OXPHEN (and its regulation by Pgc-1 signalling)
and not a delayed development of muscle OXPHEN due to impaired
myogenesis, the relevance of the work described in the present paper
lies in the direct effects of (TNF-α-induced) classical NF-κB activation
onmature skeletalmuscle oxidative phenotype in COPD. Unfortunately,
as a limitation of the present study, limited quantities of biopsy tissue
were available from the 2 previous reported clinical studies which
precluded robust assessment of classical NF-κB activity inmuscle. How-
ever, increased activation of the classical NF-κB pathway has been
described by others in skeletal muscle of severe COPD patients [14].
5. Conclusion
In conclusion, in the current manuscript we show that classical
NF-κB activation potently induces loss of skeletal muscle Ikk-α protein
abundancewhich subsequently results in an impairedmuscle OXPHEN.
This implies that reductions in Ikk-α levels underlie inﬂammation-
induced impairment of muscle OXPHEN. Moreover, our ﬁnding that
COPD patients are not only characterised by an impaired muscle
OXPHEN but also by decreased levels of IKK-α in muscle, which both
were more pronounced in patients with high levels of muscle TNF-α,
indicates that TNF-α-induced loss of muscle IKK-α levels may well be
of relevance to acute or chronic inﬂammation-induced impairments of
muscle OXPHEN in COPD. Future research into the exact implications
of both NF-κB pathways in the regulation of skeletal muscle OXPHEN
in COPD may be paramount in the development of new therapeutic
strategies.
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